5 Einträge gefunden

1. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study

   1. Reich, K
   2. Körber, A
   3. Mrowietz, U
   4. Sticherling, M
   5. Sieder, C
   6. Früh, J
   7. Bachhuber, T

   2021 - Forschungsinformationssystem des UKE
2. Continued treatment with secukinumab is associated with high retention or regain of response

   1. Augustin, M
   2. Thaci, D
   3. Eyerich, K
   4. Pinter, A
   5. Radtke, M
   6. Lauffer, F
   7. Mrowietz, U

   2020 - Forschungsinformationssystem des UKE
3. Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population

   1. Augustin, M
   2. Dauden, E
   3. Mrowietz, U
   4. Konstantinou, M P
   5. Gerdes, S
   6. Rissler, M
   7. Gathmann, S

   2020 - Forschungsinformationssystem des UKE
4. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study

   1. Reich, K
   2. Puig, L
   3. Szepietowski, J C
   4. Paul, C
   5. Lacour, J P
   6. Tsianakas, A
   7. Sieder, C

   2020 - Forschungsinformationssystem des UKE
5. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic Treatments: results from the randomized controlled PRIME trial

   1. Sticherling, M
   2. Mrowietz, U
   3. Augustin, M
   4. Thaçi, D
   5. Melzer, N
   6. Hentschke, C
   7. Kneidl, J

   2017 - Forschungsinformationssystem des UKE